Impact of ceftazidime-avibactam on mortality in bloodstream infections: a cohort study in patients with acute leukemia.

ABSTRACT:

Background

Bloodstream infections (BSI) caused by carbapenemase-producing Enterobacterales (CPE) represent a significant threat to patients with acute leukemia due to their high mortality. Ceftazidime-avibactam (CAZ-AVI) has emerged as a therapeutic alternative against these infections; however, its efficacy in immunocompromised patients remains unclear.

Objective

To determine the impact of ceftazidime-avibactam on mortality due to BSI caused by CPE in patients with acute leukemia.

Design

A retrospective cohort study was conducted at the Hospital Nacional Edgardo Rebagliati Martins in Lima, Peru.

Methods

We included patients diagnosed with acute leukemia who developed BSI due to CPE during their hospital stays. Mortality was assessed for up to 30 days af

SUBMITTER: Copaja-Corzo C 

PROVIDER: S-EPMC12357988 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature